HRP20161103T1 - Kemijski spojevi - Google Patents

Kemijski spojevi Download PDF

Info

Publication number
HRP20161103T1
HRP20161103T1 HRP20161103TT HRP20161103T HRP20161103T1 HR P20161103 T1 HRP20161103 T1 HR P20161103T1 HR P20161103T T HRP20161103T T HR P20161103TT HR P20161103 T HRP20161103 T HR P20161103T HR P20161103 T1 HRP20161103 T1 HR P20161103T1
Authority
HR
Croatia
Prior art keywords
compound
compound according
salt
intended
metabolic disorder
Prior art date
Application number
HRP20161103TT
Other languages
English (en)
Croatian (hr)
Inventor
Christopher Joseph Aquino
Jon Loren Collins
David John Cowan
Yulin Wu
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44861895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20161103T1 publication Critical patent/HRP20161103T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539Five-membered rings
    • C07F9/6541Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
HRP20161103TT 2010-04-27 2011-04-27 Kemijski spojevi HRP20161103T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32821210P 2010-04-27 2010-04-27
US32922510P 2010-04-29 2010-04-29
EP11775513.2A EP2563122B1 (en) 2010-04-27 2011-04-27 Chemical compounds
PCT/US2011/034024 WO2011137135A1 (en) 2010-04-27 2011-04-27 Chemical compounds

Publications (1)

Publication Number Publication Date
HRP20161103T1 true HRP20161103T1 (hr) 2016-11-04

Family

ID=44861895

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161103TT HRP20161103T1 (hr) 2010-04-27 2011-04-27 Kemijski spojevi

Country Status (39)

Country Link
US (1) US9040518B2 (enExample)
EP (1) EP2563122B1 (enExample)
JP (1) JP5702853B2 (enExample)
KR (1) KR101769079B1 (enExample)
CN (1) CN102858159B (enExample)
AR (1) AR081337A1 (enExample)
AU (1) AU2011245393B2 (enExample)
BR (1) BR112012026767B1 (enExample)
CA (1) CA2795543C (enExample)
CL (1) CL2012003009A1 (enExample)
CO (1) CO6612267A2 (enExample)
CR (1) CR20120557A (enExample)
CY (1) CY1118187T1 (enExample)
DK (1) DK2563122T3 (enExample)
DO (1) DOP2012000263A (enExample)
EA (1) EA021753B1 (enExample)
ES (1) ES2588743T3 (enExample)
HR (1) HRP20161103T1 (enExample)
HU (1) HUE029480T2 (enExample)
IL (1) IL222365A (enExample)
JO (1) JO3131B1 (enExample)
LT (1) LT2563122T (enExample)
MA (1) MA34235B1 (enExample)
ME (1) ME02490B (enExample)
MX (1) MX2012012527A (enExample)
MY (1) MY162933A (enExample)
NZ (1) NZ602754A (enExample)
PE (1) PE20130384A1 (enExample)
PH (1) PH12012502128B1 (enExample)
PL (1) PL2563122T3 (enExample)
PT (1) PT2563122T (enExample)
RS (1) RS55079B1 (enExample)
SG (1) SG184812A1 (enExample)
SI (1) SI2563122T1 (enExample)
SM (1) SMT201600293B (enExample)
UA (1) UA110338C2 (enExample)
UY (1) UY33353A (enExample)
WO (1) WO2011137135A1 (enExample)
ZA (1) ZA201207858B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3400944T (lt) 2010-11-04 2020-09-25 Albireo Ab Ibat inhibitoriai, skirt kepenų ligų gydymui
JP2014527071A (ja) * 2011-08-31 2014-10-09 マリンクロッド エルエルシー H−ホスホネートによるナノ粒子pegの改変
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
CA2956833C (en) * 2014-08-05 2022-08-30 Glaxosmithkline Intellectual Property (No.2) Limited Synthesis of benzothiazepines
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
CN107801396B (zh) 2015-02-02 2021-10-22 福马治疗股份有限公司 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
CA3027725C (en) 2016-06-27 2025-05-06 Glaxosmithkline Intellectual Property (No.2) Limited SYNTHESIS OF GSK23390672 BY EPOXY HYDROLASE RESOLUTION
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (es) * 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PE20210136A1 (es) 2018-06-20 2021-01-21 Albireo Ab Formulacion farmaceutica de odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
SMT202300020T1 (it) 2019-02-06 2023-03-17 Albireo Ab Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
ES2973549T3 (es) 2019-12-04 2024-06-20 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20230414634A1 (en) 2020-10-20 2023-12-28 Glaxosmithkline Intellectual Property (No.2) Limited Methods for treating cholestatic pruritus
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2024501814A (ja) * 2020-12-23 2024-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッド リネリキシバットの形態
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
KR20250029896A (ko) 2022-07-05 2025-03-05 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2024251739A1 (en) 2023-06-06 2024-12-12 Glaxosmithkline Intellectual Property (No.2) Limited Novel use of an ileal bile acid transporter inhibitor for the treatment of pruritus
WO2025078973A1 (en) 2023-10-09 2025-04-17 Assia Chemical Industries Ltd. Solid state forms of linerixibat and process for preparation thereof
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370015A (en) 1933-07-24 1945-02-20 Merck & Co Inc Derivatives of tertiary amino aliphatic acids
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
WO2002053548A1 (fr) * 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Derives de la benzothiazepine
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040077625A1 (en) 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CA2471639A1 (en) * 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
DE602004006831T2 (de) 2003-01-09 2008-02-14 Genentech, Inc., South San Francisco Reinigung von polypeptiden
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
WO2006026754A2 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
WO2010062861A2 (en) * 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes

Also Published As

Publication number Publication date
MY162933A (en) 2017-07-31
ZA201207858B (en) 2014-03-26
EA021753B1 (ru) 2015-08-31
BR112012026767B1 (pt) 2020-01-21
UA110338C2 (xx) 2015-12-25
AU2011245393B2 (en) 2014-01-23
EP2563122B1 (en) 2016-06-08
HUE029480T2 (en) 2017-02-28
PL2563122T3 (pl) 2016-12-30
EP2563122A1 (en) 2013-03-06
CL2012003009A1 (es) 2013-03-08
CR20120557A (es) 2013-02-20
UY33353A (es) 2011-12-01
EA201290909A1 (ru) 2013-05-30
CO6612267A2 (es) 2013-02-01
SMT201600293B (it) 2016-11-10
CA2795543C (en) 2017-11-28
AR081337A1 (es) 2012-08-08
PH12012502128B1 (en) 2017-11-08
EP2563122A4 (en) 2013-09-11
RS55079B1 (sr) 2016-12-30
JO3131B1 (ar) 2017-09-20
PE20130384A1 (es) 2013-04-04
LT2563122T (lt) 2016-10-10
HK1175650A1 (zh) 2013-07-12
WO2011137135A1 (en) 2011-11-03
NZ602754A (en) 2014-05-30
US9040518B2 (en) 2015-05-26
IL222365A0 (en) 2012-12-31
KR20130060201A (ko) 2013-06-07
DK2563122T3 (en) 2016-09-05
SG184812A1 (en) 2012-11-29
KR101769079B1 (ko) 2017-08-30
ES2588743T3 (es) 2016-11-04
PT2563122T (pt) 2016-09-01
CN102858159B (zh) 2015-02-11
SI2563122T1 (sl) 2016-10-28
JP5702853B2 (ja) 2015-04-15
IL222365A (en) 2016-03-31
JP2013525444A (ja) 2013-06-20
MA34235B1 (fr) 2013-05-02
CY1118187T1 (el) 2017-06-28
PH12012502128A1 (en) 2013-02-04
DOP2012000263A (es) 2013-09-15
ME02490B (me) 2017-02-20
MX2012012527A (es) 2012-12-17
CA2795543A1 (en) 2011-11-03
US20130029938A1 (en) 2013-01-31
CN102858159A (zh) 2013-01-02
BR112012026767A2 (pt) 2015-09-29

Similar Documents

Publication Publication Date Title
HRP20161103T1 (hr) Kemijski spojevi
ME02558B (me) Inhibitori replikacije virusa gripa
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
HRP20241020T1 (hr) Makrociklički spoj koji služi kao wee1 inhibitor i njegove primjene
ME02666B (me) Cefalosporin sa kateholskom grupom
HRP20130202T1 (hr) Spojevi imidazo[1,2-a] pirazina za lijeäśenje virusnih infekcija kao što je hepatitis
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20171512T1 (hr) Derivati betulina
HRP20171175T1 (hr) Novi triciklički spojevi
RU2582676C3 (ru) Некоторые химические соединения, композиции и способы
PT2323972E (pt) Compostos de tetraciclina substituídos com c7-flúor
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
EP2797881A4 (en) PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREWITH
HRP20161559T1 (hr) Derivati imidazopiridazina kao modulatori receptora gabaa
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
WO2010129057A8 (en) Tetracycline compounds
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
WO2011025982A3 (en) Tetracycline compounds
HRP20180176T1 (hr) Spojevi korisni u sintezi spojeva benzamida
JP2012512863A5 (enExample)
HRP20171425T1 (hr) Derivati oksazolidin-2-on-pirimidina
WO2011123536A8 (en) Polycyclic tetracycline compounds
HRP20180196T1 (hr) Diketoni i hidroksiketoni kao aktivatori puta signalizacije katenina
HRP20221381T1 (hr) C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta